Register
Login:
Share:
Email Facebook Twitter

Cornhill Capital sees strong investor enthusiasm in London IPOs Watch here

Cornhill Capital sees strong investor enthusiasm in London IPOs


Member Info for inanaco


Premium Member

Send a private message to inanaco

Member Since: Wed, 19th Oct 2011

Number of Share Chat Posts (all time): 24,476
Number of Share Chat Posts (last 30 days): 77

Last Posted: Sat 11:52


Post Distribution over the last 30 days




Sat 11:52

immunotherapy products showed a better long-term survival for the experimental arm. Conversely more patients died early in the experimental arm.

Depending on their level of activation the NK cells can enhance the development of a cellular immune response against an antigen but can also dampen this same response when they are stimulated beyond a given threshold.8 If this observation made with TG4010 is confirmed this could possibly apply to other situations in oncology where the NK cells are already activated by the presence of the tumor and a treatment like a therapeutic vaccine or an oncolytic virus known by essence to stimulate further the NK cells

we did not see that effect using SCIb1 ..........
Sat 11:40

To test this hypothesis a larger randomized study was initiated.6 This open-label study recently published in The Lancet Oncology enrolled 148 patients with stage IV NSCLC, 74 received cisplatine and gemcitabine plus TG4010 and 74 received the same chemotherapy alone. The primary objective was to show an improvement of progression-free survival at 6 mo. A biomarker program was also associated to the study in order to be able to identify the population of patients with the best response to chemo-immunotherapy.

With 43.2% of patients progression free at 6 mo in the experimental arm this second Phase II in NSCLC met its statistical endpoint too. In the control arm 35.1% of patients remained free of progression at 6 mo. Interestingly the magnitude of the improvement was more important on response rate: 41.9% vs. 28.4%. Furthermore the outcome in terms of survival of responding patients in the experimental arm was better than in the control arm (23.3 vs. 12.5 mo). This observation is similar to the better duration of response observed in melanoma patients receiving dacarbazine plus ipilimumab as compared with dacarbazine alone.7 Regarding overall survival the median survival in both arms were similar, 10.7 mo vs. 10.3 mo however a late separation of the curves, classic with immunotherapy products showed a better long-term survival for the experimental arm. Conversely more patients died early in the experimental arm.
Sat 11:16

I compared Inovio HPV and Transgene HPV vaccine, pointing out that Transgene had lost Roche as a partner because the perfomance of the vaccine was not great, and i pointed out Inovios results where not much better, yet Dr Kim thought they where fantastic .. So transgene pretty well iced the program ........

But now PD1 comes along ........

Transgene is planning the further development of TG4001 in combination with immune checkpoint inhibitors, a promising area of immunotherapy that Transgene believes is complementary to its own immunotherapy approach, to treat cancers caused by HPV.
In October 2016, Transgene announced it has entered a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer under which Transgene will sponsor a Phase 1/2 study evaluating the potential of TG4001 in combination with avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, for the treatment of human papilloma virus- (HPV-) positive head and neck squamous cell carcinoma (HNSCC), after failure of standard therapy.

We already know that Scancells vaccine is far more potent than Transgene ,,,,,,,,,

that is why we wait !!
Sat 11:10

Of 3 weeks does not sound much in context, however it could play an important part in longer term survival as the immune system has been reset by the chemo, with the vaccine playing its part to generate a more directed attack on the cancer. adding PD1 could alter this balance further as Scancells data has shown. Its pointless at this stage to try and compare, unless Transgene release the mouse data on its PD1 work with its vaccine
Sat 11:01

are getting involved again with vaccines after the high profile failures, reinforces our Jan 31st RNS that Big Pharma is open for business again ...... and that is why we wait .....
Fri 09:24

to that list ........ http://www.bbc.co.uk/news/health-39711137 this is why its so important to get the efficacy to commercial value spot on to value a Pharma correctly, get it wrong and its approx 8 years of investment gone !
Squandered cash ... well Governments do that very well, Corbyn might get elected on that mandate
Thu 13:46

So basically your looking for idiots that will sell you shares at 10p so you can run the rise ......... well its AIM i guess you will find them
Thu 13:39

so when i post some take the facts and twist it up for an agenda ............. and the very reason why i dig deep to find that agenda is because you cannot trust any poster on these BB's unless they have displayed years of consistent quality posts that actually make sense

and by the way Agema SCib1 is still in trial the patients are still being monitored and we do get updates.
Thu 13:34

To waiting for RNS = true result of direction

or you could make up 100 paths from this position with ease to raise the cash and still non of them would be correct

which is exactly why we don't bother

what we do know is the direction of travel to a commercial business which some seem to rewrite the rules to. as they go along

Like this statement from Agema
No product is in trials. No data coming through. Scib 1 not sold and left to run out of supplies. ( do you really think the BOD so dim as to not know the stock of vaccine for Scib 1 was running out.? ). They let it run out. No interest in
it.

when the fact is it went out of tolerance "sell by date" however nobody could predict that as it was the first batch ever manufactured and it was a least 5 years old .
Thu 13:17

Does all this happen after your last Prediction that Opti will hit a £1 ? and you will sell Opti and buy Scancell at 10p ...

if its so bad why would you buy at 10p ?


Sign up for Live Prices
Top Recommended
Hot Chat Topics
Top recommended posters in the last 30 days
Nickderby2,114
Troajan1,985
Brombarb1,758
Pdub1,699
MinorMiner1,519
Wassatt1,444
Alfacomp873
BigBiteNow854





Member Login

Forgotten your password?
Email:

Password:


Don't have an account? Click here to Register Free!




Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.